Clinical Trial Update: Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating spironolactone for hypertrophic cardiomyopathy with cardiac fibrosis; the study status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Fibrosis
• Hypertrophic Cardiomyopathy

Drugs mentioned

• Aldactone (spironolactone)

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Hypertrophic Cardiomyopathy, Fibrosis | Phase 4 | Status: UNKNOWN